Adaptive Biotechnologies Corp Stock Total Debt
| ADPT Stock | USD 4.69 0.32 7.32% |
Adaptive Biotechnologies Corp fundamentals help investors to digest information that contributes to Adaptive Biotechnologies' financial success or failures. It also enables traders to predict the movement of Adaptive Stock. The fundamental analysis module provides a way to measure Adaptive Biotechnologies' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Adaptive Biotechnologies stock.
Total Debt To Capitalization is likely to gain to 0.48 in 2024. Adaptive | Total Debt |
Adaptive Biotechnologies Corp Company Total Debt Analysis
Adaptive Biotechnologies' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Adaptive Biotechnologies Total Debt | 229.43 M |
Most of Adaptive Biotechnologies' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Adaptive Biotechnologies Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Adaptive Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for Adaptive Biotechnologies is extremely important. It helps to project a fair market value of Adaptive Stock properly, considering its historical fundamentals such as Total Debt. Since Adaptive Biotechnologies' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Adaptive Biotechnologies' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Adaptive Biotechnologies' interrelated accounts and indicators.
Click cells to compare fundamentals
Adaptive Total Debt Historical Pattern
Today, most investors in Adaptive Biotechnologies Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Adaptive Biotechnologies' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Adaptive Biotechnologies total debt as a starting point in their analysis.
Adaptive Biotechnologies Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Adaptive Net Debt
Net Debt |
|
Based on the latest financial disclosure, Adaptive Biotechnologies Corp has a Total Debt of 229.43 M. This is 91.66% lower than that of the Life Sciences Tools & Services sector and 29.36% lower than that of the Health Care industry. The total debt for all United States stocks is 95.69% higher than that of the company.
Adaptive Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Adaptive Biotechnologies' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Adaptive Biotechnologies could also be used in its relative valuation, which is a method of valuing Adaptive Biotechnologies by comparing valuation metrics of similar companies.Adaptive Biotechnologies is currently under evaluation in total debt category among its peers.
Adaptive Biotechnologies Current Valuation Drivers
We derive many important indicators used in calculating different scores of Adaptive Biotechnologies from analyzing Adaptive Biotechnologies' financial statements. These drivers represent accounts that assess Adaptive Biotechnologies' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Adaptive Biotechnologies' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 2.1B | 7.8B | 3.9B | 1.1B | 707.5M | 672.1M | |
| Enterprise Value | 2.0B | 7.7B | 3.9B | 1.1B | 871.8M | 828.3M |
Adaptive Biotechnologies ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Adaptive Biotechnologies' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Adaptive Biotechnologies' managers, analysts, and investors.Environmental | Governance | Social |
Adaptive Biotechnologies Institutional Holders
Institutional Holdings refers to the ownership stake in Adaptive Biotechnologies that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Adaptive Biotechnologies' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Adaptive Biotechnologies' value.| Shares | Geode Capital Management, Llc | 2024-09-30 | 2.7 M | State Street Corp | 2024-06-30 | 2.5 M | Blue Water Life Science Advisors, Llc | 2024-09-30 | 2.1 M | Soleus Capital Management, L.p. | 2024-06-30 | 1.7 M | Pictet Asset Manangement Sa | 2024-06-30 | 1.7 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 1.4 M | Pier Capital, Llc | 2024-09-30 | 1.3 M | Bank Of America Corp | 2024-06-30 | 1.1 M | Goldman Sachs Group Inc | 2024-06-30 | 1 M | Viking Global Investors Lp | 2024-09-30 | 30 M | Rubric Capital Management Lp | 2024-06-30 | 14 M |
Adaptive Fundamentals
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (1.10) % | ||||
| Operating Margin | (0.70) % | ||||
| Current Valuation | 540.64 M | ||||
| Shares Outstanding | 147.58 M | ||||
| Shares Owned By Insiders | 1.92 % | ||||
| Shares Owned By Institutions | 93.97 % | ||||
| Number Of Shares Shorted | 8.96 M | ||||
| Price To Earning | 0.25 X | ||||
| Price To Book | 3.09 X | ||||
| Price To Sales | 3.90 X | ||||
| Revenue | 170.28 M | ||||
| Gross Profit | (13.66 M) | ||||
| EBITDA | (189.27 M) | ||||
| Net Income | (225.25 M) | ||||
| Cash And Equivalents | 383.74 M | ||||
| Cash Per Share | 2.69 X | ||||
| Total Debt | 229.43 M | ||||
| Debt To Equity | 0.21 % | ||||
| Current Ratio | 3.93 X | ||||
| Book Value Per Share | 1.52 X | ||||
| Cash Flow From Operations | (156.32 M) | ||||
| Short Ratio | 9.71 X | ||||
| Earnings Per Share | (1.34) X | ||||
| Target Price | 7.42 | ||||
| Number Of Employees | 709 | ||||
| Beta | 1.45 | ||||
| Market Capitalization | 692.15 M | ||||
| Total Asset | 661.13 M | ||||
| Retained Earnings | (1.14 B) | ||||
| Working Capital | 322.17 M | ||||
| Current Asset | 118.69 M | ||||
| Current Liabilities | 59.26 M | ||||
| Net Asset | 661.13 M |
About Adaptive Biotechnologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Adaptive Biotechnologies Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Adaptive Biotechnologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Adaptive Biotechnologies Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Adaptive Stock Analysis
When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.